http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2595720-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2e9d9698b51d1ea8620cd50360e01591 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C213-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C213-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C211-27 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C217-62 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C213-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C217-62 |
| filingDate | 2010-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f52b92e2b9a54897454252e8cbe80429 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3069b0802116c7405366fa4b34402d5d |
| publicationDate | 2016-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2595720-C2 |
| titleOfInvention | Cognitive ability reduction inhibitors |
| abstract | FIELD: chemistry. n SUBSTANCE: invention relates to novel compounds of formula I or pharmaceutically acceptable salts thereof, which possess properties of binding Abeta-oligomers with respect to nerve cells in patients. In formula I n ; n R 1 is (A1); R 2 and R 3 , each represents H; R 4 and R 5 , each independently selected from OH and C 1-6 alkoxy group; R 6 represents H; R 7 represents H, C 1-6 alkyl, C 1-6 halogenalkyl or C 3-7 cycloalkyl; R 8 is C 1-6 alkyl, C 1-6 halogenalkyl or C 3-7 cycloalkyl; R 9 represents H or C 1-6 alkyl; R 10 represents H, C 1-6 alkyl, C 1-6 halogenalkyl or C 3-7 cycloalkyl; R 11 represents H; R 12 and R 13 , each represents H; R 14 is selected from halogen and C 1-6 halogenalkyl; R 15 and R 16 , each represents H. Preferable compounds are 4-(3-(4-chlorobenzylamino)butyl)-2-methoxyphenol or 4-(3-(4-(trifluoromethyl)benzylamino)butyl)-2-methoxyphenol. Said compounds are obtained by reacting a ketone of formula X with an amine of formula XI n ; n under reductive amination conditions with separation of corresponding compounds. Output of products is 80-95 wt%. Ginger oil containing a ketone of formula X can be used as a starting compound. n EFFECT: compounds can be useful in treating cognitive abilities, for example in Alzheimer's disease. n 18 cl, 4 dwg, 8 ex |
| priorityDate | 2009-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 161.